Physician profile
Adil Vural
NPI 1194354100
$2,361.06
in general payments reported to CMS, 2019-2025
12 companies · $833 in 2025
The $833 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $32.05 · 2021: $267 · 2022: $302 · 2023: $361 · 2024: $567 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,651 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,650.99 |
| Education | $109.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $519.40 | 2023-2025 | Tavneos, Uplizna, Evenity |
| Astrazeneca Pharmaceuticals LP | $461.81 | 2024-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.14 | 2020-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $217.21 | 2024 | |
| Alexion Pharmaceuticals, INC. | $208.84 | 2021-2023 | Strensiq |
| Gilead Sciences, INC. | $189.25 | 2022-2023 | Veklury |
| Merck Sharp & Dohme LLC | $183.57 | 2020-2023 | Recarbrio, Zerbaxa, Dificid |
| Glaxosmithkline, LLC. | $102.40 | 2025 | Benlysta |
| Janssen Biotech, INC. | $99.00 | 2025 | Tremfya |
| Insmed, INC. | $55.14 | 2022 | |
| La Jolla Pharmaceutical Company | $22.96 | 2023 | Xerava |
| Aurinia Pharma U.S., INC. | $20.34 | 2023 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adil Vural listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.